维普中文期刊产品整合服务
10篇 您的检索式:作者名="Xavier FE"
    题名 作者 年代 出处 被引量
1Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study显示文摘AIM To evaluate the real-world effectiveness of golimumab in ulcerative colitis(UC) and to identify predictors of response.METHODS We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at wk 0 and 14 with the physician's global clinical assessment(PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database.RESULTS Thirty-three consecutive patients with moderately to severely active UC were included. Among them, 54.5% were female and 42 years was the average age. Thirty percent had left-sided UC(E2) and 70% had extensive UC(E3). All patients had an endoscopic Mayo score of 2 or 3 at baseline. Twenty-seven point three percent were anti-tumor necrosis factor(TNF) treatment na?ve, whereas 72.7% had previously received infliximab and/or adalimumab. Sixty-nine point seven percent showed clinical response and were steroid-free at wk 14(a decrease from baseline in the partial Mayo score of at least 3 points). Based on PGA, the clinical remission and clinical response rates were 24% and 55% respectively. Withdrawal of corticosteroids was observed in 70.8% of steroid-dependent patients at the end of the study. Three out of 10 clinical non-responders needed a colectomy. Mean fecal calprotectin value at baseline was 300 μg/g, and 170.5 μg/g at wk 14. Being anti-TNF treatment na?ve was a protection factor, which was related to better chances of reaching clinical remission. Twenty-seven point three percent of the patients required treatment intensification at 14 wk of followup. Only three adverse effects(AEs) were observed during the study; all were mild and golimumab was not interrupted.CONCLUSION This real-life practice study endorses golimumab's promising results, demonstrating its short-term effectiveness and confirming it as a safe drug during the induction phase.Marta Maia Bosca-Watts Xavier Cortes Marisa Iborra Jose Maria Huguet Laura Sempere Gloria Garcia Rafa Gil Mari Fe Garcia Marga Munoz Pedro Almela Nuria Maroto Jose Maria Paredes 2016World Journal of Gastroenterology2016,22,47:5
2Contribution of the endothelin and rennin-angiotensin system to the vascular changes in rats chronically treated with ouabain显示文摘Xavier FE Yogi A Callera GE 2004Br J Pharmacol2004,143,6:1
3Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain显示文摘Xavier FE Yogi A Callera GE 2004Br J Pharmacol2004,143,6:1
4Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats : the role of vascular mechanism显示文摘Xavier FE Davel AP Fukuda LE 2009Hypertens2009,27,:1
5Long - term ouabain treatment impairs vascular function in resistance arteries 显示文摘Weneeslau CF Davel AP Xavier FE 2011Vase Res2011,48,:1
6Chronic ouaba- in treatment exacerbates blood pressure elevation in spon- taneously hypertensive rats: The role of vascular mecha- nisms显示文摘Xavier FE Dave1 AP Fukuda LE 2009J Hypertens2009,27,6:1
7Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain显示文摘 Yogi A Callera GE 2004Br J Pharmacol2004,143,6:1
8Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain显示文摘 Yogi A Callera GE 2004Br J Pharmacol2004,143,6:1
9Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain显示文摘Xavier FE Yogi A Callera GE 2004Br J Pharmacol2004,143,6:1
10Implant osseointegration in circumferential bone defects treated with latex-derived proteins or autogenous bone in dog's mandible显示文摘Manfrin AF Xavier SP Pinto FE 0,,01:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费